Stockholm

timeline for review of MAA in Europe.

Calliditas Therapeutics

AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm - CALTX; Nasdaq - CALT), a biopharma

company focused on identifying, developing and commercializing novel treatments in orphan indications, today announced that the European

Medicine Agency's (EMA) Committee for Human Medicinal Products (CHMP)) has decided to continue the assessment of the marketing

authorization application (MAA) for Nefecon under standard procedure assessment timelines.

Calliditas was in April,

2021 granted an accelerated assessment procedure on its MAA for Nefecon in IgA Nephropathy and submitted the MAA in May of 2021.

With the revised standard assessment timeline Calliditas estimates a potential impact of 3 months on the previously communicated timelines

with an expected decision by EMA in the first quarter, 2022.

time that EMA is assessing an application for conditional approval in IgA nephropathy and we acknowledge the need for an in depth review

under standard assessment timelines. We look forward to engaging with the agency to achieve a potential approval for this very deserving

patient population as soon as possible." said Ren e Aguiar-Lucander, CEO at Calliditas.

If approved, Nefecon could

be available to patients in Europe in mid-2022 and would become the first therapy specifically designed and approved for the treatment

of IgAN, and which has the potential to be disease modifying.

For further information,

Ren e Aguiar-Lucander,

E-mail: renee.lucander@calliditas.com

Marie Galay, Corporate

Communications and IR

Tel.: +44 7955 129 845,

e-mail: marie.galay@calliditas.com

the press release is inside information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information

was submitted for publication, through the agency of the contact persons above, on September 16, 2021 at 14:30 (CEST).

Calliditas Therapeutics

is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications,

with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon,

is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of adults

with the autoimmune renal disease primary IgA nephropathy (IgAN), for which there is a high unmet medical need and there are no approved

treatments. Calliditas read out topline data from Part A of its global Phase 3 study in IgAN in November 2020 and, if approved,

aims to commercialize Nefecon in the United States. Calliditas is also planning to start clinical trials with NOX inhibitors in primary

biliary cholangitis and head and neck cancer. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended,

including, without limitation, statements regarding Calliditas' strategy, business plans and focus. The words "may,"

"will," "could," "would," "should," "expect," "plan," "anticipate,"

"intend," "believe," "estimate," "predict," "project," "potential,"

"continue," "target" and similar expressions are intended to identify forward-looking statements, although not

all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's

current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events

or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including,

without limitation, any related to Calliditas' business, operations, the potential for and timing of EMA approval of its regulatory

marketing application for Nefecon, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other biopharmaceutical

companies, and other risks identified in the section entitled "Risk Factors" in Calliditas' reports filed with the

Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak

only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any

change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood

that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this

press release represent Calliditas' views only as of the date hereof and should not be relied upon as representing its views as

of any subsequent date.